RESEARCH DESIGN, STATISTICS, AND EVALUATING ONCOLOGY LITERATURE.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to successfully:
1.Evaluate the oncology literature, including study design, identification of sources of bias,methodology, statistical analysis, and applicability of results to clinical practice for theoncology patient population.
2.Interpret the validity and results of various types of oncology studies (e.g., meta-analyses,noninferiority trials).
3.Interpret findings from the use of study endpoints (e.g., objective response, time toprogression, adverse events, quality of life, overall survival) in oncology research.
4.Interpret sensitivity, specificity, positive and negative predictive values, measures of effect,correlation, and regression for an oncology study.
PHARMACOGENOMICS in ONCOLOGY.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Identify appropriate considerations for genetic interpretation in both the germline and somaticsettings utilizing a variety of next generation sequencing techniques.
2.Apply the results from somatic and germline genetic testing into therapy recommendationsbased on prognostic, predictive and patient characteristics.
3.Recognize the place in therapeutic decision making for companion diagnostic testing.
LOWER GASTROINTESTINAL AND PANCREATIC CANCERS.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient‐specific treatment, supportive care, and monitoring plan takinginto consideration efficacy and safety outcomes from clinical trials and current treatmentguidelines for patients with lower gastrointestinal (GI) or pancreatic cancers.
2.Discuss short‐ and long‐term treatment goals, including post‐therapy and survivorship, with apatient with lower GI or pancreatic cancers and his or her caregiver.
3.Select relevant information and guidance for the public regarding lower GI and pancreaticcancer-related issues (e.g., risk factors, prevention, screening).
4.Develop an appropriate plan for preventing, monitoring, and treating adverse reactionsassociated with pharmacotherapy for lower GI or pancreatic cancers, including chemotherapy-induced diarrhea, hand‐foot syndrome, hand-foot skin reaction, neurotoxicity from oxaliplatin,and dermatologic toxicities from epidermal growth factor receptor inhibitors.
Lec – 01
01:04:11
Lec – 02
00:00
Lec – 03
00:00
Lec – 04
00:00
CUTANEOUS MELANOMA and NON-MELANOMA SKIN CANCERS.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient-specific treatment, supportive care, and monitoring plan takinginto consideration efficacy and safety outcomes from clinical trials and current treatmentguidelines for patients with melanoma or non-melanoma skin cancer.
2.Discuss short- and long-term goals, including post-therapy and survivorship, with a patient withmelanoma or non-melanoma skin cancer and his or her caregiver.
3.Select relevant information and guidance for the public regarding melanoma and non-melanoma skin cancer-related issues (e.g., risk factors, prevention, screening).
4.Develop an appropriate plan for preventing, monitoring, and treating adverse reactionsassociated with the treatment of melanoma and non-melanoma skin cancers, including thyroidlevel monitoring for chemotherapy agents, immune-mediated toxicities, and toxicity from BRAFinhibitors.
HEAD, NECK, ADULT CENTRAL NERVOUS SYSTEM (CNS), AND THYROID MALIGNANCIES.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient‐specific treatment, management, and monitoring plan taking intoconsideration efficacy and safety outcomes from clinical trials and current treatment guidelinesfor patients with head, neck, adult central nervous system (CNS), or thyroid cancers.
2.Select relevant information and guidance for the public regarding head and neck cancer-relatedissues (e.g., risk factors, prevention, screening).
3.Develop an appropriate plan for preventing, monitoring, and treating adverse reactionsassociated with the treatment of cancers including cancer cachexia, mucositis, and xerostomia.
CHRONIC LEUKEMIAS.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient‐specific treatment, supportive care, and monitoring plan takinginto consideration relevant molecular biology testing, genomic information, efficacy and safetyoutcomes from clinical trials, and current treatment guidelines for patients with chronicleukemia.
2.Develop an appropriate plan for preventing, monitoring, and treating infusion‐related reactionsfrom monoclonal antibodies used in the treatment of hematologic malignancies.
3.Develop an appropriate plan for preventing, monitoring, and treating adverse reactionsassociated with pharmacotherapy for the treatment of cancers, including toxicities fromtyrosine kinase inhibitors used to treat hematologic cancers.
MULTIPLE MYELOMA.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient‐specific treatment, supportive care, and monitoring plan takinginto consideration efficacy and safety outcomes from clinical trials and current guidelines forpatients with multiple myeloma.
2.Evaluate oncology pharmacy services for compliance with established REMS regulations andstandards.
3.Develop an appropriate plan for preventing, monitoring, and managing common problemsassociated with the treatment of cancers, including bone metastases in multiple myeloma,thromboembolism, hypercalcemia of malignancy, and spinal cord compression.
UPPER GASTROINTESTINAL AND HEPATOCELLULAR CARCINOMAS.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient-specific treatment, management, and monitoring plan taking intoconsideration efficacy and safety outcomes from clinical trials and current treatment guidelinesfor patients with esophageal, gastric, or hepatic malignancies.
2.Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticanceragents used for gastrointestinal malignancies.
3.Develop an appropriate plan for preventing, monitoring, and treating radiation recall and othercomplications of radiation therapy.
Lec – 01
00:00
Lec – 02
00:00
Lec – 03
00:00
Lec – 04
00:00
ONCOLOGY PRACTICE MANAGEMENT.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Evaluate oncology pharmacy services for compliance with established regulations, professionalpractice standards, and procedures for handling, administration, and disposal of hazardousdrugs.
2.Select quality-improvement activities that enhance the safety and effectiveness of themedication-use process in oncology patient care.
3.Explain national accreditation and federal regulatory requirements for the care of cancerpatients receiving chemotherapy or other hazardous drugs.
4.Explain medication reimbursement and patient assistance programs to optimize drug availabilityfor oncology patients.
5.Evaluate policies and procedures related to conducting research involving investigational drugs,including drug management in patients with cancer.
NON‐HODGKIN AND HODGKIN LYMPHOMAS.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient‐specific treatment, supportive care, and monitoring plan toinclude effectiveness, toxicities and outcomes, based on the most current guidelines for patientswith lymphoma.
2.Assess the prognostic impact of relevant cancer‐related molecular biology testing.
3.Develop an appropriate plan for preventing, monitoring, and treating adverse reactionsassociated with pharmacotherapy for lymphoma and other cancers, including chemotherapy-induced pulmonary toxicities and extravasation.
BREAST CANCER.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient-specific treatment, supportive care, and monitoring plan takinginto consideration efficacy and safety outcomes from clinical trials and current treatmentguidelines for patients with breast cancer.
2.Discuss short- and long-term treatment goals, including post-therapy and survivorship, with apatient with breast cancer and her or his caregiver.
3.Determine appropriate pharmacotherapy for a patient with breast cancer based on genomictest results.
4.Identify appropriate diagnostic and prognostic tests related to breast cancer.
5.Select relevant information and guidance for the public regarding breast cancer-related issues(e.g., cancer risk factors, prevention, screening).
Lec – 01
00:00
Lec – 02
00:00
Lec – 03
00:00
Lec – 04
00:00
HEMATOPOIETIC STEM CELL TRANSPLANTATION.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient‐specific treatment, supportive care, and monitoring plan takinginto consideration efficacy and safety outcomes from clinical trials and current guidelines forpatients undergoing hematopoietic stem cell transplantation (HSCT).
2.Apply appropriate strategies to prevent and treat toxicity from chemotherapy agents employedin HSCT conditioning regimens.
3.Create a plan for prevention and management of acute and chronic graft‐versus‐host disease(GVHD) using appropriate systemic and ancillary therapies.
4.Discuss short‐ and long‐term treatment goals, including post-therapy and survivorship, with thepatient undergoing HSCT and his or her caregiver.
Learner tip: Information in bold and information contained in tables is considered more testable for the BCOP examination. Information in regular font is either background information or not supported by rigorous clinical trials or guidelines.
Lec – 01
00:00
Lec – 02
00:00
Lec – 03
00:00
Lec – 04
00:00
ADULT SARCOMAS.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1. Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for adult patients with sarcoma.
2. Adjust treatment and monitoring plans as needed based on the tumor genetics and pharmacokinetics of anticancer and supportive-care agents (e.g., methotrexate).
3. Develop an appropriate plan for preventing, monitoring, and managing common problems associated with the treatment of adult patients with cancer, including neurotoxicity from ifosfamide and hemorrhagic cystitis.
LUNG CANCER.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient-specific treatment, supportive care, and monitoring plan takinginto consideration efficacy and safety outcomes from clinical trials and current treatmentguidelines for patients with lung cancer.
2.Select relevant information and guidance for the public regarding lung cancer-related issues(e.g., risk factors, prevention, screening).
3.Develop an appropriate plan for preventing, monitoring, and treating adverse reactionsassociated with pharmacotherapy for lung cancer.
4.Develop a prevention and management strategy for chemotherapy-induced nausea andvomiting for patients with any type of cancer.
PEDIATRIC MALIGNANCIES AND SUPPORTIVE CARE.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient-specific treatment, supportive care, and monitoring plan takinginto consideration efficacy and safety outcomes from clinical trials and current treatmentguidelines for pediatric patients with cancer.
2.Assess the prognostic impact of relevant cancer-related molecular biology testing for apediatric patient with cancer.
3.Discuss with a pediatric patient who has cancer and his or her caregiver the short- and long-term treatment goals, including post-therapy and survivorship.
4.Assess the regulatory, ethical, and patient rights issues related to conducting research,including informed consent and confidentiality.
Lec – 01
00:00
Lec – 02
00:00
Lec – 03
00:00
PROSTATE CANCER.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient-specific treatment, supportive care, and monitoring plan takinginto consideration efficacy and safety outcomes from clinical trials and current treatmentguidelines for patients with prostate cancer.
2.Discuss short- and long-term treatment goals, including post-therapy and survivorship, with apatient with prostate cancer and his caregiver.
3.Select relevant information and guidance for the public regarding prostate cancer-related issues(e.g., risk factors, prevention, screening).
Lec – 01
00:00
Lec – 02
00:00
Lec – 03
00:00
ADULT ACUTE LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient‐specific treatment, supportive care, and monitoring plan takinginto consideration efficacy and safety outcomes from clinical trials and current treatmentguidelines for adults with acute leukemia or myelodysplastic syndrome.
2.Assess the prognostic impact of relevant cancer-related molecular biology testing for an adultwith acute leukemia or myelodysplastic syndrome.
3.Develop an appropriate plan for preventing, monitoring, and treating adverse reactions frompharmacotherapy for acute leukemia and myelodysplastic syndrome in an adult, includingtumor lysis syndrome, neurotoxicity, differentiation syndrome, and cardiac toxicity from arsenictrioxide, and other agents as appropriate.
4.Determine appropriate pharmacotherapy for acute leukemia or myelodysplastic syndrome in anadult based on genomic test results.
Lec – 01
00:00
Lec – 02
00:00
Lec – 03
00:00
Lec – 04
00:00
Lec – 05
00:00
Lec – 06
00:00
Lec – 07
00:00
Pdf
00:00
BLADDER, RENAL CELL, AND TESTICULAR CANCERS.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking intoconsideration efficacy and safety outcomes from clinical trials and current treatment guidelines forpatients with bladder, renal, or testicular carcinomas.
2.Discuss short- and long-term treatment goals, including post-therapy and survivorship, with a patient withbladder, renal, or testicular carcinomas and his or her caregiver
3.Develop an appropriate plan for preventing, monitoring, and treating adverse reactions associated withthe treatment with tyrosine kinase inhibitors and mTOR inhibitors.
CANCER-RELATED INFECTIOUS DISEASES.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1.Design an appropriate patient-specific management and monitoring plan to address potentialinfection-related problems that may arise during and following cancer treatment based oncurrent guidelines for treating cancer-related infectious diseases.
2.Discuss short- and long-term treatment goals, including post-therapy, with a patient with cancer-related infectious disease and his or her caregiver.
Lec – 01
00:00
Lec – 02
00:00
Lec – 03
00:00
Lec – 04
00:00
Lec – 05
00:00
GYNECOLOGIC MALIGNANCIES.
At the end of the presentation and after reviewing the accompanying reading materials, the participant should be able to:
1. Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes of clinical trials and current treatment guidelines for a patient with a gynecologic malignancy.
2. Discuss short and long-term goals, including post-therapy and survivorship, with a patient with a gynecologic malignancy and her caregiver.
3. Select relevant information and provide guidance for the public regarding gynecologic malignancy‐related issues (e.g., risk factors, prevention, and screening).
